CAG  (often discussed as part of the combination drug CagriSema) is a long-acting synthetic peptide that mimics amylin, a hormone co-secreted with insulin. Unlike GLP-1 drugs, which primarily target the gut-brain axis, cag introduces a secondary pathway for Fat loss and glucose control. As of April 2026, clinical data from Phase 3 trials (such as REIMAGINE-2) highlight its significant advantages, particularly when paired with GLP-1.

Key Benefits & Clinical Data:

Recent data confirms that CAG acts as a “force multiplier” when combined with GLP-1 therapies, leading to weight loss levels previously only seen with bariatric surgery.

Benefit Category | Data/Findings (Phase 3 Trials)Fat Loss | 14.2% to 17.7% total body weight reduction over 68 weeks. This significantly outperforms GLP-1 monotherapy (approx. 10.2%) in comparable cohorts.

• Glucose Control | Reduced HbA1c by an average of 1.91%, compared to 1.76% for semaglutide alone.
• Visceral Fat | Significant reductions in waist circumference (avg. -13.4 cm) and overall body fat mass.
• Satiety | Enhanced “fullness” signaling through both the homeostatic (hunger) and hedonic (pleasure/reward) regions of the brain.

Mechanism of Action

Cagrilintide is a non-selective amylin receptor agonist. It works differently than standard weight-loss peptides:

• Dual Receptor Target: It binds to both amylin (AMY) and calcitonin receptors.
• Gastric Emptying: It slows the rate at which food leaves the stomach, keeping you full longer.
• Glucagon Suppression: It helps prevent the liver from releasing excess sugar into the bloodstream after meals.
• Brain Signaling: It targets the area postrema in the brain to reduce the “reward” feeling associated with eating, which helps curb cravings for high-fat/high-sugar foods.

The “CagriSema” Synergy

The most common application for this peptide is the fixed-dose combination with semaglutide.

• Complementary Pathways: While semaglutide targets GLP-1 receptors to improve insulin and lower appetite, cagrilintide targets amylin receptors to further slow digestion and boost satiety.
• Plateau Breaking: Clinical data suggest that patients who have plateaued on GLP-1 monotherapy may see renewed weight loss when cagrilintide is introduced